Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is an important electrolyte abnormality that can occur following allogeneic stem cell transplantation. We herein report the case of a 20-year-old man who developed SIADH three weeks after undergoing cord blood transplantation. Tacrolimus administration was suspected to be a cause of the disorder. In addition to restricting water intake and administering hypertonic sodium, the tacrolimus dosage was reduced, resulting in alleviation of SIADH. Therefore, tacrolimus should be recognized as an important, albeit rare, cause of drug-induced SIADH, even in patients with tacrolimus blood concentrations within the normal range. We believe that dose reduction, not discontinuation, is an effective strategy.
Introduction
Hyponatremia is a major electrolyte abnormality that can occur following allogeneic stem cell transplantation (allo-SCT), with a prevalence of 20-40%. In approximately half of these cases, hyponatremia develops due to syndrome of inappropriate antidiuretic hormone ( ADH ) secretion (SIADH) (1, 2) . The general causes of SIADH include central nervous system infection (3), malignancies, such as leukemia and lymphoma (4) , and drugs, such as chemotherapeutics and antiepileptic agents (5) . Tacrolimus (TCL), which is often used for prophylaxis against the development of acute graft-versus-host disease (GVHD) after allo-SCT, is not commonly documented as a cause of severe symptomatic hyponatremia or SIADH, although TCL-induced nephrotoxicity and hyperkalemia are widely reported (6) . We herein present a case of SIADH that developed following cord blood transplantation (CBT) in which TCL was the suspected cause of SIADH and a reduction of the TCL dosage resulted in the alleviation of this complication.
Case Report
A 20-year-old man was referred to our institution for CBT. He had been diagnosed with acute myeloid leukemia (AML without maturation having a normal karyotype and the FLT3-ITD mutation) eight months previously. A complete molecular response was achieved with induction therapy consisting of one cycle of idarubicin/cytarabine and was sustained with four courses of cytarabine-based consolidation therapy, without any major complications. The patient's laboratory data at referral were all within the normal ranges (Table) . The patient underwent CBT after receiving a myeloablative conditioning regimen (cyclophosphamide [120 mg/kg] and total body irradiation at 12 Gy) (Figure) . The cord blood graft contained 2.50×10 7 /kg of nuclear cells, including 1.32×10 5 /kg of CD34-positive cells. TCL (0.03 mg/ kg/day [1.5 mg/day per body] via continuous infusion starting on day -1) and mycophenolate mofetil (25 mg/kg/day, orally administered three times a day starting on day 0) were used for acute GVHD prophylaxis. Granulocyte alkaline phosphatase, -GTP: gamma-glutamyl transpeptidase, TP: total protein, Alb: albumin, T-bil: total bilirubin, Cre: creatinine, UA: Uric acid, BUN: blood urea nitrogen, Glc: glucose, Na: sodium, K: potassium, Cl: chloride, CRP: C-reactive protein, H: higher than normal limits, L: lower than normal limits colony-stimulating factor was initiated on day 1. Fluconazole and ursodeoxycholic acid were administered as prophylaxis against fungal infections and sinusoidal occlusive syndrome, respectively. The patient's clinical course was stable, except for the development of a pre-engraftment immune reaction (PIR) on day 5 with a high-grade fever, skin rashes, body weight gain and hyponatremia. The PIR was treated with prednisolone at a dose of 1 mg/kg. Engraftment of neutrophils was achieved on day 12. In the 2nd week after CBT, the patient's serum sodium concentration rapidly decreased to less than 120 mEq/L (Table) . An endocrinological examination performed on day 19 showed low osmolality (259 mOsm) in the serum without ADH suppression (3.70 mg/dL), as well as a high sodium concentration and osmolality in the urine (99 mEq/L and 488 mOsm, respectively). Normal renal, thyroid and adrenal function findings confirmed the diagnosis of SIADH (7, 8) . The patient's cognitive and psychiatric functions were normal, and no meningeal irritation was apparent. Brain magnetic resonance imaging (MRI) showed no abnormal findings, such as encephalitis. At that time, an elevation of the blood TCL concentration (from 12.5 to 18.6 ng/mL, although the administration dosage was held constant at 1.5 mg/day) and a reactivation of human herpes virus (HHV)-6 in serum (9.8× 10 4 mRNA copies/μL) were observed. Therefore, TCL and HHV-6 reactivation were included as possible factors in the etiology of the SIADH. In addition to restricting water intake and administering an infusion of hypertonic sodium solution, the TCL trough blood level was lowered via TCL dosage reduction from 1.5 mg/day to 1.2 mg/day, and foscarnet was administered to treat the HHV-6 reactivation. The hyponatremia gradually resolved within one week. However, the SIADH recurred on day 35 (Table) . HHV-6 reactivation was not documented with the second episode, and brain MRI was not performed. Elevation in the trough value of TCL (from 3.5 to 11.1 ng/mL), which was being administered orally (5 mg/day), strongly suggested TCL's involvement in the etiology of the SIADH. Thereafter, the TCL dosage was reduced, thus resulting in a prompt improvement of the SIADH. The doses of TCL and corticosteroids were gradually tapered over a 6-month period following CBT. SIADH has not recurred subsequently. No severe GVHD was documented during the patient's clinical course.
Discussion
SIADH is a relatively rare, but occasionally lifethreatening, complication that can occur following allo-SCT (1, 2). Severe hyponatremia has serious sequelae, including confusion, hallucinations, seizures, coma and respiratory arrest, and can be fatal (9) . The causes of SIADH are many, including malignant diseases, pulmonary diseases, disorders of the central nervous system (CNS) and drugs (3) (4) (5) 9) . Among CNS lesions, HHV-6 encephalitis is particular to a post allo-SCT status and is often associated with hyponatremia (3, 10) . One of the mechanisms involved is the elevation of serum interleukin-6, which activates ADH secretion and induces SIADH (11) . HHV-6 reactivation without encephalitis or other CNS dysfunction has rarely been reported to cause hyponatremia or SIADH. With regard to drug-induced SIADH, hypothalamic production of ADH is increased by antipsychotic, antiepileptic and anticancer drugs, such as vinca alkaloids, platinum compounds and alkylating agents, including cyclophosphamide (5). TCL, which may be responsible for hyperkalemia (6) and saltlosing nephropathy via upregulation of the Na + /K + /2Cl -cotransporter in the distal tubule (12), is a rare cause of SIADH. Only two reports have described TCL-induced SIADH: one patient developed SIADH during treatment for acute GVHD (13) , while the other developed SIADH during treatment for systemic lupus erythematosus (14) . Although the definitive pathophysiology of TCL-induced SIADH has not been examined, toxic effects on the neurohypophysis and hypothalamus, as is the case for other drugs, are suspected (5). In these two cases, SIADH was induced while TCL was within the normal blood concentration range, and the threshold of the serum TCL concentration that caused SIADH was different in each patient (13, 14) . These findings are similar to those for other TCL-induced complications, such as posterior reversible encephalopathy syndrome (15) .
In the present case, there are potential causative factors of SIADH other than elevation of the blood TCL concentration and HHV-6 reactivation. These include the PIR complication and the concomitant administration of drugs, such as cyclophosphamide, mycophenolate mofetil, prednisolone, fluconazole and ursodeoxycholic acid. PIR can be attributed to a cytokine storm induced by newly engrafted cells (16) . Hyponatremia, a typical symptom of PIR, usually recovers soon after the remission of hypercytokinemia, and the association between PIR and SIADH in this patient was weak because the SIADH occurred approximately one week after the remission of PIR. The respective contributions of the other above-mentioned drugs are likely to be negligible because their administration had already been completed or the dosage was either stable or being reduced at the onset of SIADH. Drugs responsible for SIADH alter the normal osmoreceptor control of ADH secretion via direct toxic effects on the neurohypophysis and hypothalamic system (5) . Based on these factors, we considered that the contribution of TCL was much greater in this case due to the close temporal relationship between the increase in the TCL blood concentration and the occurrence of SIADH. Other causative factors, such as pulmonary or neurological lesions or massive water intake, were also excluded based on the patient's clinical course. Reactivation of another virus, such as cytomegalovirus or Epstein-Barr virus, was not detected in PCR assays of peripheral blood samples, although a lumbar puncture was not performed because the patient did not consent to the procedure. In addition, the second SIADH episode occurred without HHV-6 reactivation but with an elevation of the TCL trough blood concentration, which strongly suggested the involvement of TCL in SIADH in this patient.
The treatment algorithm for SIADH includes fluid intake restriction and hypertonic saline infusion, in addition to elimination of causal lesions and cessation of suspected drugs (9, 17) . In the present case, we initiated foscarnet therapy and reduced (rather than discontinued) the TCL dosage. Exchanging from TCL to cyclosporine was one of the therapeutic options; however, we continued to administer TCL based on the idea that the TCL blood concentration had a threshold to cause SIADH because the patient was free of SIADH at the low TCL concentration. Indeed, the SIADH remitted following the reduction in the TCL trough blood concentration (to <15 ng/mL during infusion and <10 ng/mL during oral administration). A lower dose of TCL did not re-induce SIADH, and GVHD was not documented. This is the first reported case in which reduction of the TCL trough blood concentration resulted in SIADH remission. In the two reported TCL-induced SIADH cases, TCL was discontinued and switched to cyclosporine or corticosteroids (13, 14) .
In conclusion, we observed a rare case of SIADH that developed following CBT. We attributed the SIADH to TCL administration after carefully excluding other well-known causes. The SIADH was treated with TCL dose reduction. TCL-induced SIADH is a relatively rare and poorly recognized disorder, and TCL should be considered a potential causative agent of drug-induced SIADH.
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